National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting, 18546 [2021-07341]
Download as PDF
<![CDATA[
18546
Federal Register / Vol. 86, No. 67 / Friday, April 9, 2021 / Notices
This technology discloses
pharmaceutical compositions and
methods of use to treat SLOS and
diseases having a secondary NPC like
cellular phenotype or wherein the
disease is an inborn error in cholesterol
synthesis.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Institute of Child Health and Human
Development receives written evidence
and argument that establishes that the
grant of the license would not be
consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: March 22, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
and personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Biomedical Imaging and
Bioengineering, NACBIB, May 2021.
Date: May 19, 2021.
Open: 12:00 p.m. to 2:50 p.m.
Agenda: Report from the Institute Director,
Council members and other Institute Staff.
Place: National Institutes of Health,
Democracy II, 6707 Democracy Boulevard,
Bethesda, MD 20892 (Virtual Meeting).
Closed: 3:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Democracy II, 6707 Democracy Boulevard,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: David T. George, Ph.D.,
Associate Director, Office of Research
Administration, National Institute of
Biomedical Imaging and Bioengineering,
6707 Democracy Boulevard, Room 920,
Bethesda, MD 20892, georged@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.nibib.nih.gov/about-nibib/advisorycouncil, where an agenda and any additional
information for the meeting will be posted
when available.
Dated: April 6, 2021.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–07316 Filed 4–8–21; 8:45 am]
BILLING CODE 4140–01–P
[FR Doc. 2021–07341 Filed 4–8–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council for Biomedical Imaging and
Bioengineering.
The meeting will be open to the
public by videocast as indicated below.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
VerDate Sep<11>2014
17:45 Apr 08, 2021
Jkt 253001
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
SUMMARY:
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
FOR FURTHER INFORMATION CONTACT:
Elizabeth Pitts, Ph.D., 240–669–5299;
elizabeth.pitts@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished
information related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Polyvalent Influenza Virus-Like
Particles (VLPs) and Use as Vaccines
Description of Technology
Influenza virus is a major public
health concern, causing up to 500,000
deaths annually. The current strategy of
reformulating vaccines annually against
dominant circulating strains leads to
variable protective efficacy and is
unlikely to protect against novel
influenza viruses with pandemic
potential. Thus, there is a great need for
a vaccine that provides ‘‘universal’’
protection against influenza viruses.
This technology relates to a broadly
protective, universal influenza vaccine
candidate composed of a mixture of
virus-like particles (VLPs) expressing
the hemagglutinin protein or the
neuraminidase protein from influenza
virus strains belonging to different virus
subtypes. Vaccinating animals with a
mixture of VLPs expressing four or more
hemagglutinin subtypes provides broad
and heterosubtypic protection against
lethal challenge with influenza virus
strains in both mice and ferrets. This
vaccine technology has great potential
to provide protection against both
annual epidemic and pandemicpotential influenza viruses.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404.
Potential Commercial Applications
• Vaccines against influenza virus
• Universal influenza virus vaccine
Competitive Advantages
• Broad/universal protection against
both seasonal and pandemic-potential
influenza viruses
• Does not require yearly reformulation
as is necessary with current
commercially available influenza
vaccines
Development Stage
• In vivo data assessment (animal)
E:\FR\FM\09APN1.SGM
09APN1
]]>Agencies
[Federal Register Volume 86, Number 67 (Friday, April 9, 2021)]
[Notices]
[Page 18546]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-07341]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical Imaging and Bioengineering;
Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Advisory
Council for Biomedical Imaging and Bioengineering.
The meeting will be open to the public by videocast as indicated
below.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications and/or contract proposals, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: National Advisory Council for Biomedical
Imaging and Bioengineering, NACBIB, May 2021.
Date: May 19, 2021.
Open: 12:00 p.m. to 2:50 p.m.
Agenda: Report from the Institute Director, Council members and
other Institute Staff.
Place: National Institutes of Health, Democracy II, 6707
Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).
Closed: 3:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications and/or
proposals.
Place: National Institutes of Health, Democracy II, 6707
Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: David T. George, Ph.D., Associate Director,
Office of Research Administration, National Institute of Biomedical
Imaging and Bioengineering, 6707 Democracy Boulevard, Room 920,
Bethesda, MD 20892, [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: https://www.nibib.nih.gov/about-nibib/advisory-council, where
an agenda and any additional information for the meeting will be
posted when available.
Dated: April 6, 2021.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-07341 Filed 4-8-21; 8:45 am]
BILLING CODE 4140-01-P
